On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a special focus on emicizumab. The topics of the webinar included the following:
- Introduction to inhibitor development – who and why? (Dr. Georges-Étienne Rivard)
- How patients with inhibitors have been historically managed and what has changed (Dr. Manuel Carcao)
- Emicizumab – what is it and what do studies tell us about its effectiveness and safety (Dr. Jerry Teitel)
- Practical aspects of being on emicizumab (Vanessa Bouskill, MN, RN[EC])
- How to manage bleeds and surgery when on emicizumab (Dr. Jean St-Louis)
- The future of immune tolerance induction (ITI) therapy and bypassing agent (FEIBA/rFVIIa) (Dr. Manuel Carcao)
